Inflation Reduction Act

Senate Report Exposes Big Pharma’s Profiteering at Americans’ Expense

February 14, 2024 - On February 6, 2024, the United States Senate's Health, Education, Labor, and Pensions (HELP) Committee published a Majority Staff Report highlighting the issue of exorbitant drug prices in the United States. It focuses on the business practices of three major pharmaceutical companies — Johnson & Johnson (J&J), Merck, and Bristol Myers Squibb (BMS). The report reveals...

Read More


More Articles

500 Drugs from Over 140 Brands Are Expected to Cost More This Year

by Veronica Salib

Last week, just before the end of 2023, Reuters published an article breaking a story from data analyzed by 3 Axis Advisors, a healthcare research firm. The analysis evaluated anticipated drug price...

CMS Announces First Drugs for Medicare Price Negotiations

by Veronica Salib

Kicking off the much-awaited drug price negotiations, the United States Centers for Medicare and Medicaid Services (CMS) and the Department of Health and Human Services (HHS) — under authority...

Guiding Obesity Management by Understanding Weight Loss Drugs

by Veronica Salib

As the popularity of weight management drugs, including Ozempic, continues to rise, clinicians and healthcare professionals need a guide to the obesity drug landscape. The nuanced field of weight management continues to become more and...

Biopharmaceutical Leaders Challenge the IRA’s Innovation Implications

by Veronica Salib

On the first day of the 2023 World Medical Innovation Forum (WMIF), sponsored by Mass General Brigham Hospital and Bank of America, biopharmaceutical leaders convened a panel to challenge the Inflation Reduction Act’s (IRA)...

How Inflation, Competition, Biosimilars Affect Prescription Drug Costs

by Editorial Staff

As the inflation rate continues to rise, the healthcare industry — like every other industry — is taxed with extraordinarily high costs. Rising drug prices have caused increased healthcare expenditures and out-of-pocket costs....

Analyzing 2023 Drug List Price Increases by Pharmaceutical Companies

by Veronica Salib

In January of this year, 46brooklyn, an Ohio-based nonprofit focusing on drug pricing data in the United States, revealed its annual drug pricing data report for 2023. The organization uses and analyzes proprietary data to help shed light...

Recent Articles